Lixte Biotechnology Holdings, Inc. has expanded its collaboration with The University of Texas MD Anderson Cancer Center and pharmaceutical manufacturer GSK on an ongoing clinical trial evaluating its proprietary compound LB-100 in combination with GSK's Dostarlimab for the treatment of ovarian clear cell cancer. The trial, initiated in January 2024 and led by Amir Jazaeri, MD, at MD Anderson, has added a second site at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University under the direction of Emily M. Hinchcliff, MD, MPH, and is expected to double enrollment to 42 patients following completion of its initial 21-patient target.
This expansion represents a significant acceleration in the development of a potential new treatment for ovarian clear cell cancer, a particularly aggressive and difficult-to-treat form of ovarian cancer. The company expects data from the initial cohort to be presented in the first half of 2026, with the expanded trial potentially providing more comprehensive results about the combination therapy's effectiveness. LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies.
LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data available at https://www.lixte.com, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. The company's lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm.
LIXTE's new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. Additional information about LIXTE can be found at https://lixte.com/. The expansion of this trial to include Northwestern University's cancer center represents a strategic move to accelerate patient recruitment and potentially validate the treatment approach across multiple leading cancer research institutions.
The collaboration brings together Lixte's novel compound with GSK's established immunotherapy Dostarlimab, creating a combination therapy that targets cancer through multiple mechanisms. This multi-institutional approach involving MD Anderson, Northwestern University, and pharmaceutical partner GSK increases the trial's scientific rigor and geographical reach for patient recruitment. For patients with ovarian clear cell cancer, who often face limited treatment options and poorer outcomes compared to other ovarian cancer subtypes, this expanded trial represents hope for more effective therapeutic approaches in the future.
